EUCTR2008-004764-39-BG进行中（未招募）不适用
A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Main inclusion criteria (refer to full protocol for comprehensive list)
- •Written informed consent given by adult subjects or by the parents/legal guardian on behalf of the subject in
- •combination with the subject’ s assent, if capable of assenting, before any assessment is performed.
- •Completed all visits in study CTBM100C2303, and visit 4 of CTBM100C2303 took place not more than 5 days
- •before enrollment into this study.
- •Able to comply with all protocol requirements.
- •Use of an effective means of contraception in women of childbearing potential.
- •Clinically stable in the opinion of the investigator to be treated according to this protocol.
- •cough swab culture (or bronchoalveolar lavage [BAL]) within 6 months prior to screening and in the sputum/
- •deep-throat cough swab culture at the screening visit.
- •Able to expectorate a sputum sample at screening.
- •Use of an effective means of contraception in females of childbearing potential.
- •Clinically stable in the opinion of the investigator to be treated according to this protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Main exclusion criteria (refer to full protocol for comprehensive list)
- •Any use of inhaled anti-pseudomonal antibiotics between the termination of the core trial CTMB100C2303 and
- •the enrollment into this study.
- •Any use of systemic anti-pseudomonal antibiotics between the termination of the core trial CTMB100C2303
- •and the enrollment into this study.
- •Serum creatinine 2 mg/dl or above, BUN 40 mg/dl or above, or an abnormal urinalysis defined as 2+ or greater
- •proteinuria.
- •Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.
- •Signs and symptoms of acute pulmonary disease, e.g., pneumonia, pneumothorax.
- •Administration of any investigational drug within 30 days prior to enrollment (except for study medication in
- •CTBM100C2303).
- •Any previous exposure to tobramycin dry powder for inhalation (TIP), with the exception of study medication
- •for study CTMB100C2303.
- •Administration of loop diuretics within 7 days prior to study drug administration.
- •Initiation of treatment with chronic macrolide therapy between the termination of the core trial CTMB100C2303 and the enrollment into this study (subjects may be taking chronic macrolide therapy at the time of enrollment into CTBM100C2303E1, but they must have initiated treatment more than 28 days prior to study drug administration for CTBM100C2303 and the dosage/regimen must remain stable throughout the study).
- •Initiation of treatment with dornase alpha between the termination of the core trial CTMB100C2303 and the enrollment into this study (subjects may be taking dornase alpha at the time of enrollment into CTBM100C2303E1, but they must have initiated treatment more than 28 days prior to study drug administration
- •for CTBM100C2303 and the dosage/regimen must remain stable throughout the study).
- •Initiation of treatment with inhaled steroids (or increased dose) between the termination of the core trial CTMB100C2303 and the enrollment into this study (subjects may be taking inhaled steroids at the time of enrollment into CTBM100C2303E1, but they must have initiated treatment more than 28 days prior to study drug administration for CTBM100C2303 and the dosage/regimen must remain stable throughout the study).
- •Initiation of treatment with inhaled hypertonic saline (HS) between the termination of the core trial
- •CTMB100C2303 and the enrollment into this study (subjects may be inhaling hypertonic saline at the time of
- •enrollment into CTBM100C2303E1, but they must have initiated treatment more than 28 days prior to study
- •drug administration for CTBM100C2303 and must be on a stable regimen). In addition, patients should be
- •instructed to inhale their HS at least 30 minutes before their pulmonary function tests (PFT). Patients should be
- •consistent with the timing of taking their HS at home or clinic, prior to their PFT.
- •Personal history of abnormal hearing or family history of abnormal hearing other than typical hearing loss
- •associated with the aging process.
- •Abnormal result from any audiology testing (defined as either a unilateral pure-tone audiometry test showing
- •a threshold elevation > 20 dB at any frequency across the frequency range 0.25 kHz to 8 kHz or the absence of
- •emission at the evoked otoacoustic emission test).
- •History of sputum culture or throat swab (or BAL) culture yielding Burkholderia cepacia (B. cepacia) within
- •2 years prior to screening for CTBM100C2303 and/or sputum culture yielding B. cepacia at screening for
- •CTBM100C2303 or at enrollment
研究者
相似试验
进行中（未招募）
1 期
A clinical study to assess the long-term safety and efficacy of idebenone treatment in patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study.EUCTR2017-004279-30-DESanthera Pharmaceuticals (Switzerland) Limited266
进行中（未招募）
1 期
A clinical study to assess the long-term safety and efficacy of idebenone treatment in patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study.Duchenne Muscular Dystrophy (DMD)MedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-004279-30-BESanthera Pharmaceuticals (Switzerland) Limited266
进行中（未招募）
不适用
A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who successfully Completed Participation in Study CTBM100C2303E1.Pseudomonas aeruginosa infection in cystic fibrosis patientsMedDRA version: 12.0Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaEUCTR2009-016734-26-LVovartis Pharma Services AG100
进行中（未招募）
1 期
A clinical study to assess the long-term safety and efficacy of idebenone treatment in patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study.Duchenne Muscular Dystrophy (DMD)MedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-004279-30-NLSanthera Pharmaceuticals (Switzerland) Limited266
进行中（未招募）
1 期
A clinical study to assess the long-term safety and efficacy of idebenonetreatment in patients with Duchenne Muscular Dystrophy (DMD) whocompleted the SIDEROS study.EUCTR2017-004279-30-ITSANTHERA PHARMACEUTICALS266